Profile data is unavailable for this security.
About the company
Eisai Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Oceania), Asia and Latin America (South Korea, Taiwan, Hong Kong, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.
- Revenue in JPY (TTM)749.46bn
- Net income in JPY45.42bn
- Incorporated1941
- Employees11.08k
- LocationEisai Co LtdEisai Main Bldg., 4-6-10, KoishikawaBUNKYO-KU 112-8088JapanJPN
- Phone+81 338173700
- Fax+81 338113305
- Websitehttps://www.eisai.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kobayashi Pharmaceutical Co Ltd | 173.46bn | 20.34bn | 436.92bn | 3.53k | 20.88 | 2.03 | 16.55 | 2.52 | 268.11 | 268.11 | 2,287.06 | 2,755.17 | 0.6629 | 3.88 | 3.44 | 49,081,780.00 | 7.77 | 8.01 | 9.79 | 10.18 | 55.56 | 56.45 | 11.73 | 12.24 | 2.43 | -- | 0.0048 | 33.19 | 4.33 | 0.7037 | 1.58 | 2.45 | 29.67 | 8.88 |
| Santen Pharmaceutical Co Ltd | 302.08bn | 27.72bn | 525.24bn | 4.14k | 18.99 | 1.75 | 11.57 | 1.74 | 75.98 | 75.98 | 823.09 | 822.49 | 0.7125 | 2.83 | 3.37 | 72,896,720.00 | 6.53 | 3.62 | 8.11 | 4.44 | 60.57 | 60.14 | 9.16 | 5.90 | 1.94 | 12.70 | 0.1719 | 74.51 | 4.80 | 4.40 | -154.96 | -- | 19.87 | 4.24 |
| Rohto Pharmaceutical Co Ltd | 263.56bn | 30.90bn | 681.61bn | 7.18k | 21.36 | 2.74 | 17.19 | 2.59 | 135.10 | 135.10 | 1,152.78 | 1,052.16 | 0.806 | 2.40 | 3.82 | 36,728,540.00 | 9.52 | 7.64 | 13.00 | 10.67 | 58.20 | 58.93 | 11.81 | 9.03 | 1.98 | -- | 0.0377 | 20.27 | 19.54 | 6.80 | 24.85 | 23.21 | 12.69 | 14.87 |
| Ono Pharmaceutical Co Ltd | 498.07bn | 127.61bn | 1.15tn | 3.76k | 8.72 | 1.39 | 7.88 | 2.30 | 263.99 | 263.99 | 1,028.76 | 1,652.77 | 0.5784 | 2.67 | 3.63 | 132,430,500.00 | 14.83 | 10.70 | 16.70 | 12.27 | 75.56 | 73.39 | 25.64 | 22.41 | 3.43 | -- | 0.0107 | 34.85 | 23.75 | 11.30 | 40.00 | 17.52 | -13.44 | 11.84 |
| Kyowa Kirin Co Ltd | 442.23bn | 81.19bn | 1.42tn | 5.97k | 17.45 | 1.69 | 13.91 | 3.22 | 151.01 | 151.01 | 822.55 | 1,555.81 | 0.4499 | 1.57 | 3.81 | 74,026,450.00 | 8.26 | 6.28 | 9.43 | 7.08 | 74.85 | 75.45 | 18.36 | 14.96 | 4.05 | -- | 0.023 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
| Eisai Co Ltd | 749.46bn | 45.42bn | 1.73tn | 11.08k | 36.77 | 2.04 | 20.02 | 2.30 | 158.37 | 158.37 | 2,613.15 | 2,852.93 | 0.585 | 1.11 | 4.00 | 67,665,220.00 | 3.65 | 5.94 | 4.86 | 8.12 | 78.95 | 75.43 | 6.23 | 9.58 | 1.79 | -- | 0.1648 | 68.53 | -1.56 | 4.41 | 15.59 | 1.35 | 6.92 | 1.30 |
| Shionogi & Co Ltd | 425.16bn | 154.46bn | 2.12tn | 5.68k | 13.53 | 1.72 | 12.41 | 4.98 | 527.99 | 527.99 | 1,453.13 | 4,149.67 | 0.3244 | 0.9783 | 2.67 | 74,851,410.00 | 11.69 | 13.45 | 13.23 | 15.20 | 85.87 | 83.95 | 36.02 | 38.01 | 6.01 | -- | 0.008 | 25.23 | 27.32 | 4.36 | 61.99 | 11.18 | 16.93 | 10.49 |
| Astellas Pharma Inc | 1.54tn | 4.20bn | 2.65tn | 14.48k | 593.54 | 1.75 | 19.44 | 1.72 | 2.47 | 2.47 | 856.92 | 838.41 | 0.5247 | 1.45 | 3.26 | 106,553,700.00 | 0.1427 | 6.93 | 0.2087 | 9.72 | 81.76 | 79.67 | 0.272 | 11.41 | 0.7143 | 130.30 | 0.3669 | 56.13 | 17.16 | 3.15 | -20.45 | -9.73 | 17.06 | 10.76 |
| Otsuka Holdings Co Ltd | 2.02tn | 121.61bn | 3.46tn | 34.39k | 27.64 | 1.40 | 15.48 | 1.71 | 224.09 | 224.09 | 3,719.71 | 4,410.81 | 0.6246 | 2.58 | 4.50 | 58,699,780.00 | 3.88 | 4.80 | 4.85 | 5.88 | 69.72 | 68.21 | 6.22 | 8.36 | 1.61 | -- | 0.0808 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Takeda Pharmaceutical Co Ltd | 4.17tn | 178.22bn | 6.47tn | 49.10k | 36.25 | 0.9516 | 7.34 | 1.55 | 112.79 | 112.79 | 2,647.34 | 4,297.22 | 0.3007 | 1.29 | 5.86 | 84,917,990.00 | 1.29 | 1.79 | 1.54 | 2.14 | 67.52 | 68.57 | 4.28 | 6.81 | 0.5518 | 2.83 | 0.4089 | 121.86 | 12.85 | 17.87 | 37.80 | 11.15 | 37.64 | 0.00 |
| Chugai Pharmaceutical Co Ltd | 1.11tn | 325.47bn | 8.55tn | 7.60k | 25.73 | 5.15 | -- | 7.69 | 197.80 | 197.80 | 675.40 | 988.01 | 0.5846 | 1.46 | 2.67 | 146,155,400.00 | 17.12 | 19.29 | 21.06 | 23.91 | 62.81 | 63.55 | 29.29 | 28.39 | 3.79 | -- | 0.0082 | 40.14 | -11.78 | 13.90 | -13.08 | 28.61 | -0.8947 | 27.23 |
Data as of Apr 19 2024. Currency figures normalised to Eisai Co Ltd's reporting currency: Japanese Yen JPY
31.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Aug 2022 | 20.75m | 7.00% |
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 17.32m | 5.84% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 9.26m | 3.12% |
| Nikko Asset Management Co., Ltd.as of 29 Sep 2023 | 8.43m | 2.84% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 8.21m | 2.77% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 29 Sep 2023 | 7.92m | 2.67% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 6.34m | 2.14% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 5.10m | 1.72% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 31 Oct 2022 | 4.81m | 1.62% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 3.98m | 1.34% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
